Doliver Advisors’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-30,000
Closed -$551K – 199
2026
Q2
$551K Buy
+30,000
New +$483K 0.12% 115

Other funds holding VRDN

Doliver Advisors's VRDN Position: Q3 2026 in Review

Doliver Advisors sold out of Viridian Therapeutics (VRDN) in Q3 2026, closing a stake of 30,000 shares — an estimated $551K sold.

Doliver Advisors first reported a position in VRDN in Q2 2026 and held it in 1 quarter. The position peaked at $551K in Q2 2026. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Doliver Advisors reported no remaining Viridian Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Doliver Advisors sold 30,000 Viridian Therapeutics shares in Q3 2026, an estimated $551K.
  • Doliver Advisors first reported a position in Viridian Therapeutics in Q2 2026 and held it in 1 quarter.
  • Doliver Advisors's Viridian Therapeutics position peaked at $551K in Q2 2026.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Doliver Advisors's 13F filing for Q3 2026, filed 1 Oct 2026.